Ocular Therapeutix (NASDAQ:OCUL) Insider Sells $166,063.68 in Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Pravin Dugel sold 20,056 shares of Ocular Therapeutix stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $8.28, for a total transaction of $166,063.68. Following the completion of the transaction, the insider directly owned 3,013,022 shares of the company’s stock, valued at $24,947,822.16. This trade represents a 0.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Pravin Dugel also recently made the following trade(s):

• On Thursday, February 12th, Pravin Dugel sold 124,882 shares of Ocular Therapeutix stock. The shares were sold at an average price of $9.04, for a total value of $1,128,933.28.

Ocular Therapeutix Price Performance

Shares of NASDAQ OCUL opened at $8.94 on Friday. The stock has a market cap of $1.95 billion, a P/E ratio of -6.21 and a beta of 0.90. The firm’s 50-day simple moving average is $10.31 and its 200 day simple moving average is $11.57. Ocular Therapeutix, Inc. has a fifty-two week low of $5.78 and a fifty-two week high of $16.44. The company has a quick ratio of 15.32, a current ratio of 15.39 and a debt-to-equity ratio of 0.11.

Ocular Therapeutix (NASDAQ:OCUL) last released its earnings results on Thursday, February 5th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.04. Ocular Therapeutix had a negative return on equity of 70.68% and a negative net margin of 511.90%.The firm had revenue of $13.25 million during the quarter, compared to the consensus estimate of $16.13 million. During the same period in the prior year, the firm posted ($0.29) earnings per share. The firm’s revenue for the quarter was down 22.4% compared to the same quarter last year. Equities analysts expect that Ocular Therapeutix, Inc. will post -0.98 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Steward Partners Investment Advisory LLC grew its holdings in Ocular Therapeutix by 124.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 2,242 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 1,242 shares during the last quarter. Nisa Investment Advisors LLC boosted its position in shares of Ocular Therapeutix by 62.9% in the second quarter. Nisa Investment Advisors LLC now owns 3,604 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 1,392 shares during the period. Hilton Head Capital Partners LLC bought a new stake in shares of Ocular Therapeutix in the fourth quarter valued at approximately $42,000. Atlas Capital Advisors Inc. acquired a new stake in shares of Ocular Therapeutix in the fourth quarter worth $61,000. Finally, KBC Group NV bought a new position in Ocular Therapeutix during the fourth quarter worth $78,000. 59.21% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have issued reports on OCUL shares. Chardan Capital reissued a “buy” rating and set a $21.00 target price on shares of Ocular Therapeutix in a research note on Wednesday, February 18th. Wall Street Zen downgraded Ocular Therapeutix from a “hold” rating to a “sell” rating in a report on Saturday. HC Wainwright upped their price target on Ocular Therapeutix from $19.00 to $21.00 and gave the company a “buy” rating in a research report on Monday, December 8th. Needham & Company LLC reduced their price objective on Ocular Therapeutix from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Friday, February 20th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Ocular Therapeutix in a research note on Tuesday, February 17th. Twelve research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Ocular Therapeutix currently has a consensus rating of “Moderate Buy” and an average price target of $23.78.

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.